Duke Clinical Research Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2012

  1. Impact of IL28b gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 5, pp. 1246-1249

  2. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with All HCV genotypes

    Journal of Infectious Diseases, Vol. 205, Núm. 3, pp. 376-383

2011

  1. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin

    AIDS, Vol. 25, Núm. 8, pp. 1025-1033

  2. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy

    Journal of Infectious Diseases, Vol. 203, Núm. 11, pp. 1629-1636

  3. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline

    AIDS, Vol. 25, Núm. 2, pp. 269-271

2010

  1. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients

    AIDS, Vol. 24, Núm. 8

  2. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV

    Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216